Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug rezetecan combinations in advanced solid tumors
2024-517147-31-00Phase 2Authorised
- Sponsor
- GSK
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 2, randomised, open-label trial of mocertatug rezetecan in Nonhematologic neoplasms and gynecologic tumor (2 arms), sponsored by GSK. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 1 more. Planned start May 2025; status: authorised.
02
Drugs
mocertatug rezetecan
03
Conditions
Nonhematologic neoplasmsgynecologic tumor
Beyond the preview
Go deeper on 2024-517147-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517147-31-00.